tetano
Editor, Senior Moderator
Sci Rep
. 2022 May 23;12(1):8679.
doi: 10.1038/s41598-022-12750-z.
Longitudinal analysis of anti-SARS-CoV-2 S-RBD IgG antibodies before and after the third dose of the BNT162b2 vaccine
Bruna Lo Sasso[SUP] #[/SUP][SUP] 1 2 [/SUP], Luisa Agnello[SUP] #[/SUP][SUP] 1 [/SUP], Rosaria Vincenza Giglio[SUP] 1 2 [/SUP], Caterina Maria Gambino[SUP] 1 2 [/SUP], Anna Maria Ciaccio[SUP] 3 [/SUP], Matteo Vidali[SUP] 4 [/SUP], Marcello Ciaccio[SUP] 5 6 [/SUP]
Affiliations
Abstract
Immunosurveillance by evaluating anti-spike protein receptor-binding domain (S-RBD) antibodies represents a useful tool to estimate the long immunity against Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) infection. The aim of this study was to evaluate the kinetics of antibody response in vaccine recipients. We measured anti-S-RBD IgG levels by indirect chemiluminescence immunoassay on Maglumi 800 (SNIBE, California) in 1013 healthy individuals naïve to SARS-CoV2 infection after two and three COVID-19 vaccine doses. We found that anti-S-RBD IgG levels are higher in females than males. Antibody levels gradually decrease to a steady state after four months since the peak, and the decay is independent of age, sex, vaccine doses, and baseline antibodies titer. The third dose induces a high anti-S-RBD IgG reactivity in individuals with previous high responses and triggers a moderate-high anti-S-RBD IgG reactivity. The assessment of anti-S-RBD IgG levels is essential for monitoring long-term antibody response. A third SARS-CoV-2 vaccine dose is associated with a significant immunological response. Thus, our results support the efficacy of the vaccine programs and the usefulness of the third dose.
. 2022 May 23;12(1):8679.
doi: 10.1038/s41598-022-12750-z.
Longitudinal analysis of anti-SARS-CoV-2 S-RBD IgG antibodies before and after the third dose of the BNT162b2 vaccine
Bruna Lo Sasso[SUP] #[/SUP][SUP] 1 2 [/SUP], Luisa Agnello[SUP] #[/SUP][SUP] 1 [/SUP], Rosaria Vincenza Giglio[SUP] 1 2 [/SUP], Caterina Maria Gambino[SUP] 1 2 [/SUP], Anna Maria Ciaccio[SUP] 3 [/SUP], Matteo Vidali[SUP] 4 [/SUP], Marcello Ciaccio[SUP] 5 6 [/SUP]
Affiliations
- PMID: 35606426
- DOI: 10.1038/s41598-022-12750-z
Abstract
Immunosurveillance by evaluating anti-spike protein receptor-binding domain (S-RBD) antibodies represents a useful tool to estimate the long immunity against Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) infection. The aim of this study was to evaluate the kinetics of antibody response in vaccine recipients. We measured anti-S-RBD IgG levels by indirect chemiluminescence immunoassay on Maglumi 800 (SNIBE, California) in 1013 healthy individuals naïve to SARS-CoV2 infection after two and three COVID-19 vaccine doses. We found that anti-S-RBD IgG levels are higher in females than males. Antibody levels gradually decrease to a steady state after four months since the peak, and the decay is independent of age, sex, vaccine doses, and baseline antibodies titer. The third dose induces a high anti-S-RBD IgG reactivity in individuals with previous high responses and triggers a moderate-high anti-S-RBD IgG reactivity. The assessment of anti-S-RBD IgG levels is essential for monitoring long-term antibody response. A third SARS-CoV-2 vaccine dose is associated with a significant immunological response. Thus, our results support the efficacy of the vaccine programs and the usefulness of the third dose.